Cargando…
No association between methotrexate and impaired bone mineral density in a cohort of patients with polymyalgia rheumatica, giant cell arteritis, granulomatosis with polyangiitis and other vasculitides—a cross-sectional analysis with dose–response analyses
OBJECTIVE: To investigate whether methotrexate (MTX) use is associated with bone mineral density (BMD) in patients with polymyalgia rheumatica (PMR) and various forms of vasculitis. METHODS: Rh-GIOP is a cohort study designed to evaluate bone health in patients with inflammatory rheumatic diseases....
Autores principales: | Palmowski, Andriko, Akahoshi, Mitsuteru, Muche, Burkhard, Boyadzhieva, Zhivana, Hermann, Sandra, Terao, Chikashi, Wiebe, Edgar, Buttgereit, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073043/ https://www.ncbi.nlm.nih.gov/pubmed/36811660 http://dx.doi.org/10.1007/s00296-023-05286-6 |
Ejemplares similares
-
Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with
Polymyalgia Rheumatica, Giant Cell Arteritis and Other Vasculitides—Cross-Sectional
Baseline Analysis of the Prospective Rh-GIOP Cohort
por: Palmowski, Andriko, et al.
Publicado: (2022) -
Sex and age do not modify the association between glucocorticoids and bone mineral density in patients with rheumatoid arthritis: a cross-sectional study
por: Palmowski, Andriko, et al.
Publicado: (2023) -
Is Tocilizumab Effective and Safe in Polymyalgia Rheumatica and Giant-Cell Arteritis With Polymyalgia Rheumatica?
por: Farinango, Michelle, et al.
Publicado: (2022) -
Optimal management of giant cell arteritis and polymyalgia rheumatica
por: Charlton, Rodger
Publicado: (2012) -
Genetic epidemiology: Giant cell arteritis and polymyalgia rheumatica
por: Gonzalez-Gay, Miguel A
Publicado: (2001)